Literature DB >> 27141296

High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature.

Musa U Umar1, Aliyu A Isa2, Asmaul H Abba2.   

Abstract

Entities:  

Year:  2015        PMID： 27141296      PMCID： PMC4837965          DOI： 10.1177/2045125315616738

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN： 2045-1253


× No keyword cloud information.
  26 in total

Review 1.  Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

Authors:  Samer Alabed; Youssef Latifeh; Husam Aldeen Mohammad; Abdullah Rifai
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

Review 2.  Tardive dyskinesia in non-western countries: a review.

Authors:  A K Pandurangi; Y A Aderibigbe
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

3.  Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.

Authors:  V Lerner; A Kaptsan; C Miodownik; M Kotler
Journal:  Clin Neuropharmacol       Date:  1999 Jul-Aug       Impact factor: 1.592

Review 4.  Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia.

Authors:  Adegoke Oloruntoba Adelufosi; Olukayode Abayomi; Tunde Massey-Ferguson Ojo
Journal:  Cochrane Database Syst Rev       Date:  2015-04-13

Review 5.  Spectrum of tardive syndromes: clinical recognition and management.

Authors:  Roongroj Bhidayasiri; Suthida Boonyawairoj
Journal:  Postgrad Med J       Date:  2010-12-03       Impact factor: 2.401

6.  Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study.

Authors:  V Lerner; C Miodownik; A Kaptsan; H Cohen; M Matar; U Loewenthal; M Kotler
Journal:  Am J Psychiatry       Date:  2001-09       Impact factor: 18.112

Review 7.  Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

Authors:  J M Kane; J M Smith
Journal:  Arch Gen Psychiatry       Date:  1982-04

8.  Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia.

Authors:  Chanoch Miodownik; Aviel Meoded; Igor Libov; Yuly Bersudsky; Ben-Ami Sela; Vladimir Lerner
Journal:  Clin Neuropharmacol       Date:  2008 Jul-Aug       Impact factor: 1.592

Review 9.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

Review 10.  Tetrabenazine in the treatment of hyperkinetic movement disorders.

Authors:  Christopher Kenney; Joseph Jankovic
Journal:  Expert Rev Neurother       Date:  2006-01       Impact factor: 4.618
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.